Shifting paradigms in the pharmacogenetics of warfarin.
Gak
Eva
E
Halkin
Hillel
H
D019943:Amino Acid Substitution; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D044466:Asian People; D044383:Black People; D004305:Dose-Response Relationship, Drug; D005819:Genetic Markers; D006239:Haplotypes; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007585:Jews; D006899:Mixed Function Oxygenases / Q000235:genetics; D010597:Pharmacogenetics; D044382:Population Groups / Q000208:ethnology / Q000235:genetics; D017410:Practice Guidelines as Topic; D014443:Tyrosine / Q000378:metabolism; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D044465:White People
D000925:Anticoagulants; D005819:Genetic Markers; D014443:Tyrosine; D014859:Warfarin; D006899:Mixed Function Oxygenases; D064417:Vitamin K Epoxide Reductases